
|Videos|February 11, 2019
Expert Explains the Greatest Challenge in Treating Patients With MDS and AML
Author(s)Christopher R. Cogle, MD
Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes and acute myeloid leukemia.
Advertisement
Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Both MDS and AML are very heterogenous diseases where a patient has multiple MDS or AML clones, Cogle says. In his research, he found that there were hundreds of genomic abnormalities in each patient.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5

































